Folic Acid-Conjugated 4-Amino-Phenylboronate, a Boron-Containing Compound Designed for Boron Neutron Capture Therapy, is an Unexpected Agonist for Human Neutrophils and Platelets
Version of Record online: 18 MAR 2014
© 2013 John Wiley & Sons A/S
Chemical Biology & Drug Design
Volume 83, Issue 5, pages 532–540, May 2014
How to Cite
Achilli, C., Jadhav, S. A., Guidetti, G. F., Ciana, A., Abbonante, V., Malara, A., Fagnoni, M., Torti, M., Balduini, A., Balduini, C. and Minetti, G. (2014), Folic Acid-Conjugated 4-Amino-Phenylboronate, a Boron-Containing Compound Designed for Boron Neutron Capture Therapy, is an Unexpected Agonist for Human Neutrophils and Platelets. Chemical Biology & Drug Design, 83: 532–540. doi: 10.1111/cbdd.12264
- Issue online: 22 APR 2014
- Version of Record online: 18 MAR 2014
- Accepted manuscript online: 25 NOV 2013 11:05AM EST
- Manuscript Accepted: 15 NOV 2013
- Manuscript Revised: 9 NOV 2013
- Manuscript Received: 5 SEP 2013
- CARIPLO Foundation. Grant Number: 2009-2440
- IRCCS San Matteo Foundation
Data S1. Characterization of FPB-pinacol ester.
Data S2. Characterization of FPB.
Figure S1. Positive ion mass spectra of FPB performed by ESI-MS.
Figure S2. (A) RP-HPLC chromatogram of FPB. (B) Comparison between the HPLC chromatograms of FPB and FA.
Figure S3. Effect of BPA and FPB on erythrocytes.
Figure S4. FPB-induced platelet aggregation depends on integrin αIIbβ3 and requires the activation of phospholipase C.
Figure S5. FPB induces aggregation of platelets in autologous plasma.
Figure S6. FPB increases the extent of thrombus formation under flow.
Figure S7. Analysis of megakaryocyte viability and proplatelet production after treatment with boronate compounds.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.